News Releases

Date Title and Summary Additional Formats
Toggle Summary HTG Molecular Diagnostics Provides Regulatory Update for its HTG EdgeSeq ALKPlus Assay
Company Intends to Submit Fourth and Final Module for PMA in Second Quarter of 2018 TUCSON, Ariz. , Sept. 11, 2017 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq:HTGM), a provider of instruments, reagents and services for molecular profiling applications, today announced that it
View HTML
Toggle Summary HTG Molecular Diagnostics to Present at the Rodman & Renshaw 19th Annual Investment Conference
TUCSON, Ariz. , Sept. 06, 2017 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq:HTGM), a provider of instruments, reagents and services for molecular profiling applications, today announced its management will present at the Rodman and Renshaw 19 th Annual Global Investment Conference in
View HTML
Toggle Summary HTG Molecular Diagnostics’ Technology to be Used in WIN Consortium NSCLC Clinical Trial
TUCSON, Ariz. , Aug. 09, 2017 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics , Inc. (Nasdaq:HTGM), a provider of instruments, reagents, and services for molecular profiling applications, today announced that its HTG EdgeSeq technology will be used together with Illumina next-generation sequencing
View HTML
Toggle Summary HTG Molecular Diagnostics Reports Second Quarter 2017 Results
Provides 2017 Revenue Guidance of $9.0 million to $12.0 million TUCSON, Ariz. , Aug. 08, 2017 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics , Inc. (NASDAQ:HTGM) (HTG), a provider of instruments, reagents and services for molecular profiling applications, today reported financial results for the
View HTML
Toggle Summary HTG Molecular Diagnostics Announces Second Companion Diagnostic Development Project with QIAGEN
Developing NGS Gene Expression Profiling Assays for Multiple Cancer Therapies TUCSON, Ariz. and VENLO, the Netherlands , July 27, 2017 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc.  (Nasdaq:HTGM) (“HTG”), a provider of instruments, reagents and services for molecular profiling applications
View HTML
Toggle Summary HTG Molecular Diagnostics to Present at the Canaccord Genuity Growth Conference
TUCSON, Ariz. , July 26, 2017 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq:HTGM), a provider of instruments, reagents and services for molecular profiling applications, today announced its management will be presenting at the Canaccord Genuity 37th Annual Growth Conference on
View HTML
Toggle Summary HTG Molecular Diagnostics to Hold 2017 Second Quarter Financial Results Conference Call on August 8, 2017
TUCSON, Ariz. , July 18, 2017 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics , Inc. (Nasdaq:HTGM), a provider of instruments, reagents, and services for molecular profiling applications, today announced that the Company will release 2017 second quarter financial results after market close on
View HTML
Toggle Summary HTG Molecular Diagnostics Launches its HTG EdgeSeq PATH Assay
TUCSON, Ariz. , June 28, 2017 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics , Inc. (Nasdaq:HTGM), a provider of instruments, reagents and services for molecular profiling applications, announced that it has launched its new HTG EdgeSeq PATH Assay for sale in the U.S. and Europe .
View HTML
Toggle Summary HTG Molecular Diagnostics Participating in WIN 2017 Symposium
TUCSON, Ariz. , June 26, 2017 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics , Inc. (Nasdaq:HTGM), a provider of instruments, reagents and services for molecular profiling applications, announced its participation in WIN 2017 Symposium, dedicated to Expediting Global Innovation in Precision Cancer
View HTML
Toggle Summary HTG Molecular Diagnostics Expands Its IVD Agreement With Illumina to Increase the Number of Test Kits
TUCSON, Ariz. , June 05, 2017 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics , Inc. (Nasdaq:HTGM), a provider of instruments, reagents and services for molecular profiling applications, announced that it has amended and restated its IVD Test Development and Component Supply Agreement with Illumina
View HTML